Asunto(s)
Hormona del Crecimiento/sangre , Hormona del Crecimiento/deficiencia , Hormona del Crecimiento/uso terapéutico , Pediatría/historia , Glándula Tiroides/fisiología , Tirotropina/uso terapéutico , Niño , Femenino , Historia del Siglo XX , Humanos , Yodo/uso terapéutico , Estudios ProspectivosAsunto(s)
Síndrome de Klinefelter/historia , Pediatría/historia , Publicaciones Periódicas como Asunto/historia , Testosterona/historia , Andrógenos/historia , Andrógenos/uso terapéutico , Niño , Historia del Siglo XX , Humanos , Síndrome de Klinefelter/tratamiento farmacológico , Testosterona/uso terapéuticoRESUMEN
The treatment of adolescent males with hypogonadism using testosterone is dependent on the underlying diagnosis as well as the patient's and family's preferences. Those with testicular failure, always a pathologic condition, begin lifelong therapy, while short-term therapy is often begun for those who have a delayed puberty. There is a wide variety of testosterone formulations available, with differences in adverse events sometimes associated with the method of administration. The goals of treatment involve stimulating physical puberty, including achievement of virilization, a normal muscle mass and bone mineral density for age, and improvement in psychosocial wellbeing. While androgen therapy results in physical changes of puberty, the potential for fertility must be considered for those with permanent gonadotropin deficiency. in this population, therapy with gonadotropins or gonadotropin releasing hormone may be effective. For those with testicular failure, fertility may be possible but requires assisted reproductive procedures.
Asunto(s)
Hipogonadismo/tratamiento farmacológico , Pubertad Tardía/tratamiento farmacológico , Testosterona/análogos & derivados , Adolescente , Andrógenos/uso terapéutico , Niño , Humanos , Masculino , Testosterona/uso terapéuticoRESUMEN
Peripheral precocious puberty (PPP) refers to the early onset of sexual maturation that is independent of central nervous system control. The extensive differential diagnosis includes congenital and acquired causes. Presenting features depend on which class of sex steroids is involved, and diagnosis rests on hormonal and, if indicated, imaging and/or genetic studies. Effective treatment exists for nearly all causes of PPP. Ongoing research will advance our therapeutic armamentarium and understanding of the pathophysiologic basis of these conditions.
Asunto(s)
Pubertad Precoz , Humanos , Pubertad Precoz/terapia , Pubertad Precoz/diagnóstico , Niño , FemeninoRESUMEN
Delayed puberty is defined as absent testicular enlargement in boys or breast development in girls at an age that is 2 to 2.5 SDS later than the mean age at which these events occur in the population (traditionally, 14 years in boys and 13 years in girls). One cause of delayed/absent puberty is hypogonadotropic hypogonadism (HH), which refers to inadequate hypothalamic/pituitary function leading to deficient production of sex steroids in males and females. Individuals with HH typically have normal gonads, and thus HH differs from hypergonadotropic hypogonadism, which is associated with primary gonadal insufficiency.
Asunto(s)
Hipogonadismo , Humanos , Masculino , Femenino , Adolescente , Pubertad Tardía/etiología , Pubertad Tardía/diagnósticoRESUMEN
Spanning from bench to bedside, the history of normal and precocious puberty is characterized by a series of remarkable advances that have illuminated reproductive physiology and profoundly impacted clinical care. Early recognition of the hypothalamic and pituitary control of ovarian and testicular function led to the identification of GnRH as the key driver of pubertal onset. Decades later, discovery of the kisspeptin system further refined our understanding of human reproductive neuroendocrinology. Development of long-acting analogs of GnRH revolutionized the treatment of precocious puberty worldwide and ushered in the current era of an ever-expanding therapeutic armamentarium. Identification of monogenic etiologies of precocious puberty has further illustrated the exquisite complexity that comprises neurosecretory modulation of the hypothalamic GnRH neuron and may well lead to exciting novel targeted therapies.
Asunto(s)
Hormona Liberadora de Gonadotropina , Pubertad Precoz , Pubertad , Humanos , Hormona Liberadora de Gonadotropina/fisiología , Neuroendocrinología , Neuronas/fisiología , Pubertad/fisiología , Pubertad Precoz/tratamiento farmacológicoRESUMEN
Importance: Appropriately established pediatric reference intervals are critical to the clinical decision-making process and should reflect the physiologic changes that occur during healthy child development. Reference intervals used in pediatric care today remain highly inconsistent across a broad range of common clinical biomarkers. Observations: This narrative review assesses biomarker-specific pediatric reference intervals and their clinical utility with respect to the underlying biological changes occurring during development. Pediatric reference intervals from PubMed-indexed articles published from January 2015 to April 2021, commercial laboratory websites, study cohorts, and pediatric reference interval books were all examined. Although large numbers of pediatric reference intervals are published for some biomarkers, very few are used by clinical and commercial laboratories. The patterns, extent, and timing of biomarker changes are highly variable, particularly during developmental stages with rapid physiologic changes. However, many pediatric reference intervals do not capture these changes and thus do not accurately reflect the underlying biochemistry of development, resulting in significant inconsistencies between reference intervals. Conclusions and Relevance: There is a need to correctly describe the biochemistry of child development as well as to identify strategies to develop accurate and consistent pediatric reference intervals for improved pediatric care.
Asunto(s)
Familia , Biomarcadores , Niño , Toma de Decisiones Clínicas , Humanos , Valores de ReferenciaRESUMEN
PURPOSE: Many birth-assigned female/transgender male and nonbinary people (identified as masculine spectrum here) begin gender-affirming testosterone therapy by the age of 24 years. Few data inform assessment of cardiovascular health of masculine spectrum youth as a specific subgroup of the 1.5 million transgender people in the United States. The purpose of this review is to help youth-serving practitioners consider, understand, and evaluate cardiovascular health in adolescent and young adult masculine spectrum patients receiving gender-affirming testosterone treatment. METHODS: This is a narrative review intended to synthesize a broad body of clinical and research literature. RESULTS: Common cardiovascular health changes associated with testosterone include increased red blood cell mass and likely insignificant changes in high-density lipoprotein and low-density lipoprotein levels. Changes in heart mass, heart electrophysiology, and endothelial reactivity are likely, based on extrapolation of data from adults. Testosterone may have indirect effects on cardiovascular health through influences on depression, anxiety, stress, and anorexia nervosa as well as on behaviors such as tobacco use. CONCLUSIONS: Testosterone contributes importantly to the cardiovascular health and well-being of masculine spectrum gender-diverse youth. We need to do a better job of supporting these young people with data on cardiovascular health over the life span.
Asunto(s)
Personas Transgénero , Transexualidad , Adolescente , Adulto , Ansiedad , Femenino , Identidad de Género , Humanos , Masculino , Testosterona , Estados Unidos , Adulto JovenRESUMEN
It is estimated that a significant percentage of individuals with spina bifida (SB) are shorter than their age-matched typical peers. Parents of children with spina bifida may ask if human growth hormone is appropriate for their child. This article discusses short stature and the use of human growth hormone among children with SB. This guideline was developed for SB Healthcare Guidelines from the 2018 Spina Bifida Association's Fourth Edition of the Guidelines for the Care of People with Spina Bifida.
Asunto(s)
Enanismo/complicaciones , Enanismo/tratamiento farmacológico , Hormona de Crecimiento Humana/uso terapéutico , Guías de Práctica Clínica como Asunto , Disrafia Espinal/complicaciones , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Disrafia Espinal/rehabilitación , Adulto JovenRESUMEN
Children with spina bifida are at greater risk of developing central precocious puberty (CPP) compared to others. Therefore, early recognition and timely referral for further evaluation by a pediatric endocrinologist allows appropriate management that reduces the impact of CPP. This article discusses the diagnosis and management of CPP in children with spina bifida. This guideline was developed for SB Transition Healthcare Guidelines from the 2018 Spina Bifida Association's Fourth Edition of the Guidelines for the Care of People with Spina Bifida.
Asunto(s)
Guías de Práctica Clínica como Asunto , Pubertad Precoz/complicaciones , Pubertad Precoz/terapia , Disrafia Espinal/complicaciones , Adolescente , Adulto , Femenino , Humanos , Masculino , Persona de Mediana Edad , Disrafia Espinal/rehabilitación , Adulto JovenRESUMEN
The care of individuals with disorders/differences of sex development aims to enable affected individuals and their families to have the best quality of life, particularly those born with severe genital ambiguity. Two of the biggest concerns for parents and health professionals are: (1) making a gender assignment and (2) the decisions of whether or not surgery is indicated, and if so, when is best for the patient and parents. These decisions, which can be overwhelming to families, are almost always made in the face of uncertainties. Such decisions must involve the parents, include multidisciplinary contributions, have an underlying principle of full disclosure, and respect familial, philosophical, and cultural values. Assignment as male or female is made with the realization that gender identity cannot be predicted with certainty. Because of the variability among those with the same diagnosis and complexity of phenotype-genotype correlation, the use of algorithms is inappropriate. The goal of this article is to emphasize the need for individualized care to make the best possible decisions for each patient's unique situation.
Asunto(s)
Trastornos del Desarrollo Sexual , Identidad de Género , Trastornos del Desarrollo Sexual/diagnóstico , Trastornos del Desarrollo Sexual/terapia , Femenino , Humanos , Masculino , Padres , Calidad de Vida , Desarrollo SexualRESUMEN
Since 2003, the GH MonitorSM, an observational registry, has collected data on pediatric subjects treated with Saizen (recombinant human growth hormone (r-hGH)) in the United States and Canada. This article provides an update on the demographic characteristics of subjects enrolled in the GHMonitorSM Registry. As of August 2007, 1733 subjects were enrolled (68.9% male). The most common primary diagnosis at screening was idiopathic growth hormone deficiency (56.5% of subjects).Of those subjects with available data, mean height standard deviation (SD) score was -2.1+/-1.0, mean weight SD score was -1.4+/-1.5, and mean body mass index SD score was -0.1+/-1.3. Among subjects in whom the presence or absence of other pituitary hormone deficiencies was recorded, 16.1% had multiple pituitary hormone deficiencies. Most patients reported high compliance with therapy (92.6% missed 0-3 doses per month); compliance was similar for all delivery devices (needle/syringe, cool.clickTM or one.clickTM) used. Two serious adverse events related to Saizen (hospitalization for placement of right frontal ventriculostomy and right frontal craniotomy for transcallosal resection of a large recurrent craniopharyngioma and left slipped capitofemoral epiphysis that required pinning of the right hip) were reported in the period from August 2006 to August 2007. This update of the GHMonitorSM Registry continues to provide insight into the characteristics of children treated with this agent and continued evidence of the efficacy and safety of Saizen in children.
Asunto(s)
Trastornos del Crecimiento/tratamiento farmacológico , Hormona de Crecimiento Humana/uso terapéutico , Adolescente , Niño , Preescolar , Femenino , Hormona de Crecimiento Humana/efectos adversos , Humanos , Lactante , Masculino , Hormonas Hipofisarias/deficiencia , Proteínas Recombinantes/efectos adversos , Proteínas Recombinantes/uso terapéutico , Sistema de Registros , Adulto JovenRESUMEN
PURPOSE: The purpose of the study was to describe the novel use of bicalutamide in transgender youth. METHODS: This is a retrospective review of patients with gender dysphoria followed in the pediatric endocrine clinic at Riley Hospital for Children. RESULTS: Of 104 patients with gender dysphoria, 23 male-to-female adolescents received bicalutamide 50 mg daily as a second-line puberty blocker after insurance company denial of a gonadotropin-releasing hormone analog. Six patients received estrogen concurrently. Of 13 patients treated exclusively with bicalutamide seen in follow-up, 84.6% had breast development within 6 months, the majority being ≥ Tanner stage III. CONCLUSIONS: Bicalutamide may be an alternative to gonadotropin-releasing hormone analogs in transgender male-to-female youth who are also ready to undergo physical transition.
Asunto(s)
Antagonistas de Andrógenos/administración & dosificación , Anilidas/administración & dosificación , Feminización/tratamiento farmacológico , Disforia de Género/terapia , Nitrilos/administración & dosificación , Compuestos de Tosilo/administración & dosificación , Personas Transgénero/estadística & datos numéricos , Adolescente , Niño , Femenino , Humanos , Estudios Longitudinales , Masculino , Estudios Retrospectivos , Maduración Sexual/efectos de los fármacos , Personas Transgénero/psicologíaRESUMEN
This update, written by authors designated by multiple pediatric endocrinology societies (see List of Participating Societies) from around the globe, concisely addresses topics related to changes in GnRHa usage in children and adolescents over the last decade. Topics related to the use of GnRHa in precocious puberty include diagnostic criteria, globally available formulations, considerations of benefit of treatment, monitoring of therapy, adverse events, and long-term outcome data. Additional sections review use in transgender individuals and other pediatric endocrine related conditions. Although there have been many significant changes in GnRHa usage, there is a definite paucity of evidence-based publications to support them. Therefore, this paper is explicitly not intended to evaluate what is recommended in terms of the best use of GnRHa, based on evidence and expert opinion, but rather to describe how these drugs are used, irrespective of any qualitative evaluation. Thus, this paper should be considered a narrative review on GnRHa utilization in precocious puberty and other clinical situations. These changes are reviewed not only to point out deficiencies in the literature but also to stimulate future studies and publications in this area.
Asunto(s)
Hormona Liberadora de Gonadotropina/uso terapéutico , Pubertad Precoz , Adolescente , Niño , Femenino , Humanos , Masculino , Pubertad Precoz/diagnóstico , Pubertad Precoz/tratamiento farmacológico , Pubertad Precoz/patología , Pubertad Precoz/fisiopatologíaRESUMEN
Accurate measurement of the low levels of testosterone (T) and estradiol (E(2)) present in normal children and in children with disorders of puberty and sexual development is critical both for appropriate diagnosis and treatment and for clinical research studies. However, measurement of these levels lacks needed precision because of inadequate sensitivity of most commercially available assays and poor accuracy at the low levels found in normal childhood and most disorders. While immunoassays presently do not appear to have the potential to provide more accurate measurements, isotope dilution-gas chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry techniques offer promise to meet this need to improve clinical care and research.
Asunto(s)
Enfermedades del Sistema Endocrino/diagnóstico , Estradiol/sangre , Testosterona/sangre , Bioensayo/métodos , Bioensayo/normas , Niño , Cromatografía Liquida/métodos , Femenino , Cromatografía de Gases y Espectrometría de Masas/métodos , Humanos , Masculino , Valores de Referencia , Sensibilidad y Especificidad , Espectrometría de Masas en Tándem/métodosRESUMEN
The GHMonitor observational registry collates data on pediatric subjects receiving Saizen (recombinant human growth hormone (GH)) therapy. From January 2003 through August 2006, 1335 subjects were enrolled in the registry, approximately two-thirds of whom are male. The most common diagnosis in the registry is idiopathic growth hormone deficiency (58%). Most subjects in GHMonitor are receiving Saizen doses using a needle-free delivery device, the cool.click (73%). Mean height standard deviation scores show an improvement from -2.1 at screening to -1.1 following 3 years of Saizen therapy. To date, adverse events have been reported in 4% of subjects. Three serious adverse events were identified to be related to Saizen by the primary investigator: cellulitis at the injection site, behavioral problems/suicidal ideation, and enlargement of a craniopharyngioma. This article provides an update on data from the registry and briefly discusses topical and controversial issues in the treatment of pediatric patients requiring GH therapy.